Abstract Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes and obesity, have evolved into multi-organ potential therapeutics due to their pleiotropic effects beyond glycemic control
The insulinotropic effects of GLP-1, and the reduction of its effects in type 2 diabetes mellitus (T2DM), have made GLP-1 an attractive option for the treatment of T2DM
The typical lipid profile pattern that accompanies obesity includes elevated triglycerides, reduced HDL-C, elevated non-HDL-C, elevated apoB, and increased proportion of LDL-C [10, 13]
Symptoms can include: chest pain when exercising dizziness fainting for no apparent reason feeling that your heart is pounding, racing, or skipping a beat severe pain, pressure, or tightness in your chest, arm, throat, neck, or jaw shortness of breath nausea and vomiting cold sweat drooping on one side of the face sudden weakness or numbness in one arm slurred speech or trouble speaking Problems with blood circulation in your fingers and toes, such as Raynauds syndrome
.jpg)
